Tearsheet
Investment Highlights Market Valuation Price Chart Business Description Interactive Breakdown Latest Trefis Analyses Better Bets vs. WBA Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

Walgreens Boots Alliance (WBA)

Market Price (9/16/2025): $12.05 | Market Cap: $10.4 Bil
Sector: Consumer Staples | Industry: Drug Retail

Walgreens Boots Alliance (WBA)

Market Price (9/16/2025): $12.05
Market Cap: $10.4 Bil
Sector: Consumer Staples
Industry: Drug Retail

Investment Highlights

0 Attractive yield
FCF Yield is 5.6%		  Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -2.9 Bil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1.9%
1   Debt is significant
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 272%
2   Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -65%
0 Attractive yield
FCF Yield is 5.6%
1 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -2.9 Bil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1.9%
2 Debt is significant
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 272%
3 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -65%

Market Valuation

 9/16/252024202320222021
Share Price CYE$12.05$9.33$24.14$32.22$42.99
Market Cap CYE ($ Bil)10.48.120.827.837.2
Total Debt ($ Bil)29.032.933.535.533.4
Total Cash ($ Bil)0.83.10.72.51.2
Enterprise Value ($ Bil)38.641.054.363.370.6
Valuation Ratios     
P/S TTM0.10.10.20.20.3
P/EBIT TTM-1.9-0.6-4.77.415.6
P/E TTM-1.6-0.9-7.37.517.8
Sector Ratios     
P/S TTM (Sector)0.90.90.90.91.6
P/EBIT TTM (Sector)8.58.910.09.411.6
P/E TTM (Sector)12.712.114.012.016.2
 9/16/2520242023
Share Price CYE$12.05$9.33$24.14
Market Cap CYE ($ Bil)10.48.120.8
Total Debt ($ Bil)29.032.933.5
Total Cash ($ Bil)0.83.10.7
Enterprise Value ($ Bil)38.641.054.3
Valuation Ratios   
P/S TTM0.10.10.2
P/EBIT TTM-1.9-0.6-4.7
P/E TTM-1.6-0.9-7.3
Sector Ratios   
P/S TTM (Sector)0.90.90.9
P/EBIT TTM (Sector)8.58.910.0
P/E TTM (Sector)12.712.114.0

Market Cap Chart

Business Description

Walgreens Boots Alliance, Inc. operates as a pharmacy-led health and beauty retail company. It operates through two segments, the United States and International. Show more

Price Returns Compared

Expand for Detailed View

 202020212022202320242025Total [1]
Returns
WBA Return-29%36%-25%-25%-61%-100%�
Peers Return29%28%-18%17%22%14%120%
S&P 500 Return16%27%-19%24%23%12%104%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: AMZN, WMT, CVS, KR, TGT.
[3] 2025 data is for the year up to 9/15/2025 (YTD)

Interactive Breakdown

Walgreens Boots Alliance Interactive Breakdown Analysis

Latest Trefis Analyses

TitleTopicDate
0DASHBOARDS  
1Walgreens Boots Alliance Earnings Notes  
2How Does WBA Stack Up Against Its Peers?Peer Comparison 
3WBA Dip Buy Analysis  
4Walgreens Boots Alliance During 2008 Recession vs. 2022 Inflation Shock: WBA Stock Has 305% Upside If It Recovers To Pre-Inflation Shock Levels Actionable 
5Walgreens Boots Alliance (WBA) Valuation Ratios ComparisonFinancials 
6Walgreens Boots Alliance Total Shareholder Return (TSR): -60.7% in 2024 and -39.9% 3-yr compounded annual returns (below peer average)  
7Walgreens Boots Alliance (WBA) worth $9.5 Bil (up $1.2 Bil), more valuable than GeneracNotification 
8Walgreens Boots Alliance (WBA) Operating Cash Flow ComparisonFinancials 
9Walgreens Boots Alliance (WBA) Net Income ComparisonFinancials 
10Walgreens Boots Alliance (WBA) Operating Income ComparisonFinancials 
11ARTICLES  
12What’s Next For WBA Stock After Its Recent 27% Rise? January 13th, 2025
13Why Did Walgreens Stock Jump 18%? December 11th, 2024
14What’s Next For Walgreens Stock After A 20% Rally? October 17th, 2024
15Should You Avoid Walgreens Stock Ahead Of Q4 Results? October 10th, 2024
16Bitter Pill To Swallow: Why Walgreens Stock Is Down 60% This Year August 28th, 2024
Title
0DASHBOARDS
1What’s Next For WBA Stock After Its Recent 27% Rise?
2Why Did Walgreens Stock Jump 18%?
3What’s Next For Walgreens Stock After A 20% Rally?
4Should You Avoid Walgreens Stock Ahead Of Q4 Results?
5Bitter Pill To Swallow: Why Walgreens Stock Is Down 60% This Year
6ARTICLES
7Walgreens Boots Alliance Earnings Notes
8How Does WBA Stack Up Against Its Peers?
9WBA Dip Buy Analysis
10Walgreens Boots Alliance During 2008 Recession vs. 2022 Inflation Shock: WBA Stock Has 305% Upside If It Recovers To Pre-Inflation Shock Levels 
11Walgreens Boots Alliance (WBA) Valuation Ratios Comparison
12Walgreens Boots Alliance Total Shareholder Return (TSR): -60.7% in 2024 and -39.9% 3-yr compounded annual returns (below peer average)
13Walgreens Boots Alliance (WBA) worth $9.5 Bil (up $1.2 Bil), more valuable than Generac
14Walgreens Boots Alliance (WBA) Operating Cash Flow Comparison
15Walgreens Boots Alliance (WBA) Net Income Comparison
16Walgreens Boots Alliance (WBA) Operating Income Comparison

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1NXTTNext Technology18985.5%1080.3%
2BDSXBiodesix1658.4%-75.2%
3VCIGVCI Global1460.0%-66.8%
4CLSDClearside Biomedical1075.2%-72.3%
5SDOTSadot806.7%-78.2%
6WLDSWearable Devices539.8%-24.4%
7QMMMQMMM536.6%5505.5%
8ATCHAtlasClear382.9%-89.7%
9OPIOffice Properties Income Trust274.5%-8.3%
10CWDCaliberCos246.5%-46.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1DGNXDiginex-83.7% 
2ATYRaTyr Pharma-81.4%-72.0%
3LGCLLucas GC-73.2%-78.3%
4NAKAKindly MD-72.8% 
5OCTOEightco-67.8%562.1%
6YYGHYY-67.0%-78.2%
7SNTGSentage-58.1%57.5%
8REXREX American Resources-50.7%-26.7%
9BINIBollinger Innovations-49.2%-100.0%
10SLXNSilexion Therapeutics-49.2%-88.0%

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1PMIPicard Medical11963.5%11963.5%
2GIBOGIBO7309.3% 
3CHSNChanson International5551.3%-99.3%
4LNZALanzaTech Global5145.9%-85.7%
5QMMMQMMM2490.3%5505.5%
6NXTTNext Technology2167.7%1080.3%
7VTAKCatheter Precision1543.9%-70.5%
8CURXCuranex Pharmaceuticals1282.0%1282.0%
9VCIGVCI Global1278.3%-66.8%
10OCTOEightco800.6%562.1%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1CJETChijet Motor-93.3%-95.1%
2ELPWElong Power-92.4%-76.5%
3STFSStar Fashion Culture-92.1%-97.9%
4ETSElite Express-92.0%-92.0%
5NAKAKindly MD-91.7% 
6BINIBollinger Innovations-90.5%-100.0%
7FLYEFly-E-89.8%-81.2%
8JEM707 Cayman-89.8%-98.3%
9NUTRNusaTrip-86.7%-86.7%
10CUPRCuprina-84.9% 

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1NXTTNext Technology18985.5%1080.3%
2BDSXBiodesix1658.4%-75.2%
3VCIGVCI Global1460.0%-66.8%
4CLSDClearside Biomedical1075.2%-72.3%
5SDOTSadot806.7%-78.2%
6WLDSWearable Devices539.8%-24.4%
7QMMMQMMM536.6%5505.5%
8ATCHAtlasClear382.9%-89.7%
9OPIOffice Properties Income Trust274.5%-8.3%
10CWDCaliberCos246.5%-46.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1DGNXDiginex-83.7% 
2ATYRaTyr Pharma-81.4%-72.0%
3LGCLLucas GC-73.2%-78.3%
4NAKAKindly MD-72.8% 
5OCTOEightco-67.8%562.1%
6YYGHYY-67.0%-78.2%
7SNTGSentage-58.1%57.5%
8REXREX American Resources-50.7%-26.7%
9BINIBollinger Innovations-49.2%-100.0%
10SLXNSilexion Therapeutics-49.2%-88.0%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Walgreens Boots Alliance

Financials

WBAAMZNWMTCVSKRTGTMedian
NameWalgreen.Amazon.c.Walmart CVS Heal.Kroger Target  
Mkt Price-231.43103.6973.4667.4188.5688.56
Mkt Cap10.42,461.7827.292.644.540.368.6
Rev LTM154,580670,038693,153378,960146,972105,640266,770
Op Inc LTM-2,87476,19028,98810,8983,8775,4248,161
FCF LTM58013,48113,7535,9411,8442,9444,442
FCF 3Y Avg-37821,67714,98610,4912,2763,2826,886
CFO LTM1,577121,13738,4388,7605,6016,3867,573
CFO 3Y Avg1,20296,97736,70713,2346,0427,47010,352

Growth & Margins

WBAAMZNWMTCVSKRTGTMedian
NameWalgreen.Amazon.c.Walmart CVS Heal.Kroger Target  
Rev Chg LTM6.2%10.9%4.2%5.0%-2.1%-1.5%4.6%
Rev Chg 3Y Avg4.8%11.3%5.7%8.1%1.4%-0.7%5.2%
Rev Chg Q7.2%13.3%4.8%7.0%-0.3%-0.9%5.9%
QoQ Delta Rev Chg LTM1.7%3.0%1.2%1.6%-0.1%-0.2%1.4%
Op Mgn LTM-1.9%11.4%4.2%2.9%2.6%5.1%3.5%
Op Mgn 3Y Avg-2.8%7.9%4.0%3.8%2.4%5.1%3.9%
QoQ Delta Op Mgn LTM-0.0%0.3%-0.1%0.2%0.0%-0.3%0.0%
CFO/Rev LTM1.0%18.1%5.5%2.3%3.8%6.0%4.7%
CFO/Rev 3Y Avg0.8%15.8%5.5%3.8%4.1%7.0%4.8%
FCF/Rev LTM0.4%2.0%2.0%1.6%1.3%2.8%1.8%
FCF/Rev 3Y Avg-0.3%3.5%2.3%3.0%1.5%3.1%2.7%

Valuation

WBAAMZNWMTCVSKRTGTMedian
NameWalgreen.Amazon.c.Walmart CVS Heal.Kroger Target  
Mkt Cap10.42,461.7827.292.644.540.368.6
P/S0.13.71.20.20.30.40.3
P/EBIT-1.928.926.69.111.87.310.4
P/E-1.634.938.817.517.210.217.4
P/CFO6.620.321.510.67.96.39.3
Total Yield-60.8%2.9%3.4%9.3%7.8%14.8%5.6%
Dividend Yield0.0%0.0%0.9%3.6%2.0%5.1%1.4%
FCF Yield 3Y Avg-2.0%1.1%2.8%12.5%6.1%5.6%4.2%
D/E2.80.10.10.90.00.50.3
Net D/E2.70.00.10.70.00.40.2

Returns

WBAAMZNWMTCVSKRTGTMedian
NameWalgreen.Amazon.c.Walmart CVS Heal.Kroger Target  
1M Rtn-0.2%3.7%7.1%-3.3%-14.0%0.2%
3M Rtn-7.1%10.2%9.7%2.6%-8.1%7.1%
6M Rtn-18.2%19.4%12.6%2.5%-14.3%12.6%
12M Rtn-24.1%29.9%32.5%23.0%-39.2%24.1%
3Y Rtn-87.3%142.7%-19.5%52.5%-40.5%52.5%
1M Excs Rtn--2.1%0.5%7.8%-4.4%-17.3%-2.1%
3M Excs Rtn--1.6%-0.6%-0.6%-7.3%-16.8%-1.6%
6M Excs Rtn--0.4%5.1%-3.1%-12.7%-30.8%-3.1%
12M Excs Rtn-6.3%13.7%17.8%14.5%-56.7%13.7%
3Y Excs Rtn-13.1%71.8%-84.7%-16.1%-107.9%-16.1%

Comparison Analyses

Financials

$ Mil | FY: 8/312025Q32025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q22023Q12022Q4
Period End5/31/20252/28/202511/30/20248/31/20245/31/20242/29/202411/30/20238/31/20235/31/20232/28/202311/30/20228/31/2022
Filing Date6/26/20254/8/20251/10/202510/15/20246/27/20243/28/20241/4/202410/12/20236/27/20233/28/20231/5/202310/13/2022
Key Financials Quarterly            
Total Revenue38,98638,58839,45937,54736,35137,05236,70735,42235,41534,86233,38232,449
Ebitda624-3,506209-245971-12,3623573853881,308-4,665-165
Operating Income13-1,956-236-69567-880-80-514-535121-6,205-910
Net Income-175-2,853-265-3,005344-5,908-67-180118703-3,721-415
EPS-0.20-3.30-0.31-3.480.40-6.85-0.08-0.210.140.81-4.31-0.48
Key Financials TTM            
Total Revenue TTM154,580151,945150,409147,657145,532144,596142,406139,081136,108133,290132,184132,703
Ebitda TTM-2,918-2,571-11,427-11,279-10,649-11,2322,438-2,584-3,134-2,954-2,6916,374
Operating Income TTM-2,874-2,820-1,744-1,588-1,407-2,009-1,008-7,133-7,529-7,441-6,419969
Net Income TTM-6,298-5,779-8,834-8,636-5,811-6,037574-3,080-3,315-3,144-2,9644,337
Growth Rates Quarterly            
Total Revenue Growth7.2%4.1%7.5%6.0%2.6%6.3%10.0%9.2%8.6%3.3%-1.5%-5.3%
EBITDA Growth-35.7%71.6%-41.5%-163.6%150.3%-1045.1%107.7%333.3%-31.7%-16.7%-206.0%-110.9%
Operating Income Growth-80.6%-122.3%-195.0%-35.2%112.5%-827.3%98.7%43.5%-19.7%-89.4%-624.5%-206.7%
Net Income Growth-150.9%51.7%-295.5%-1569.4%191.5%-940.4%98.2%56.6%-59.2%-20.4%-203.9%-166.2%
Margins Quarterly            
EBITDA Margin1.6%-9.1%0.5%-0.7%2.7%-33.4%1.0%1.1%1.1%3.8%-14.0%-0.5%
Operating Income Margin0.0%-5.1%-0.6%-1.9%0.2%-2.4%-0.2%-1.5%-1.5%0.3%-18.6%-2.8%
Net Income Margin-0.4%-7.4%-0.7%-8.0%0.9%-15.9%-0.2%-0.5%0.3%2.0%-11.1%-1.3%
Cash & Debt            
Total Cash8301,1321,1913,1097036687847399701,8404,2322,472
Total Debt29,03430,13430,70832,85232,67633,62333,73733,53436,43937,57835,51135,478
Net Debt / (Cash)28,20429,00229,51729,74331,97332,95532,95332,79535,46935,73831,27933,006
Cash Flows Quarterly            
FCF from Operations584-199-1401,332604-637-2811,039-2074649386
Cash Flows TTM            
FCF from Operations TTM1,5771,5971,1591,0187251011,4842,2581,3052,9543,2933,899
Returns to Shareholders Quarterly            
Dividends0216216216216413415415415414415408
Share Repurchases-0-036-0-0-069-0-0-0150-0
Return on Invested Capital (ROIC) Quarterly            
ROIC0.2%-25.6%-3.2%-9.3%0.8%-10.0%-0.8%-3.7%-0.8%1.2%-57.6%-7.6%
Return on Invested Capital (ROIC) TTM            
ROIC TTM-10.2%-9.7%-5.9%-5.3%-4.1%-5.5%-0.1%-14.3%-14.1%-13.7%-13.5%2.9%

Price Behavior

WBA Betas & Captures as of 8/31/2025

 1M2M3M6M1Y3Y
Beta-0.03-0.010.050.250.110.55
Up Beta-0.63-0.43-0.330.160.060.55
Down Beta0.070.010.020.390.270.58
Up Capture32%36%32%29%15%8%
Bmk +ve Days10223571142415
Stock +ve Days12223462117337
Down Capture-12%-1%3%24%-11%93%
Bmk -ve Days11192754106334
Stock -ve Days6141953119397

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
6/26/20250.6%1.6%2.8%
4/8/2025-1.1%1.9%3.2%
1/10/202527.5%40.2%8.1%
10/15/202415.8%16.1%0.1%
6/27/2024-22.2%-29.1%-24.5%
3/28/20243.2%-9.7%-15.8%
1/4/2024-5.1%-3.5%-11.5%
10/12/20237.0%-6.0%-9.5%
...
SUMMARY STATS   
# Positive121210
# Negative121214
Median Positive5.0%4.3%6.9%
Median Negative-6.2%-6.6%-9.6%
Max Positive27.5%40.2%20.5%
Max Negative-22.2%-29.1%-24.5%

SEC Filings

Expand for More

Report DateFiling DateFiling
5312025626202510-Q 5/31/2025
2282025408202510-Q 2/28/2025
11302024110202510-Q 11/30/2024
83120241015202410-K 8/31/2024
5312024627202410-Q 5/31/2024
2292024328202410-Q 2/29/2024
11302023104202410-Q 11/30/2023
83120231012202310-K 8/31/2023
5312023627202310-Q 5/31/2023
2282023328202310-Q 2/28/2023
11302022105202310-Q 11/30/2022
83120221013202210-K 8/31/2022
5312022630202210-Q 5/31/2022
2282022331202210-Q 2/28/2022
11302021106202210-Q 11/30/2021
83120211014202110-K 8/31/2021

Insider Activity

Expand for More

 OwnerTitleFiling DateActionPriceSharesTransacted
Value		Value of
Held Shares		Form
0Pessina StefanoExecutive Chairman of Board4292025Sell11.01832,2589,163,1617,236,961Form

External Quote Links


Prefer one of these to Trefis? Tell us why.